Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Health-related quality of life after IMRT or IMRT+ HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial. This is an ASCO Meeting Abstract from the ...
In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...
"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.
Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...
The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...
When it comes to detecting cancer, you want the fastest detection possible in order to treat it accurately and in a timely ...
While many people are familiar with mammograms and smear tests, prostate screening is talked about far less.To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...
Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC). This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results